Ursodesoxycholic acid and heme-arginate are unable to improve hematopoiesis and liver injury in an erythropoietic protoporphyria mouse model

Physiological Research

Volumn 55, Issue SUPPL. 2, 2006, Pages

  Abitbol, M ^a   Puy, H ^b   Sabate J M ^c   Guenet J L ^a   Deybach, J Ch ^b   Montagutelli, X ^a  

^a INSTITUT PASTEUR   (France)

^b HÔPITAL LOUIS MOURIER   (France)

^c NONE

Author keywords

Erythropoietic protoporphyria; Heme; Mouse model; Ursodesoxycholate

Indexed keywords

ARGININE; CHOLAGOGUE; HEME; HEME ARGINATE; URSODEOXYCHOLIC ACID;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; ERYTHROPOIETIC PROTOPORPHYRIA; HEMATOPOIESIS; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER; METABOLISM; MOUSE; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; ARGININE; CHOLAGOGUES AND CHOLERETICS; DISEASE MODELS, ANIMAL; HEMATOPOIESIS; HEME; INJECTIONS, INTRAPERITONEAL; LIVER; MICE; MICE, TRANSGENIC; PROTOPORPHYRIA, ERYTHROPOIETIC; URSODEOXYCHOLIC ACID;

EID: 33847191722     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. ANDERSON KE, SASSA S, BISHOP DF, DESNICK RJ: The porphyrias. In: The metabolic basis of inherited diseases. CR SCRIVER, AL BEAUDET, WS SLY, D VALLE (eds), Mac Graw-Hill Inc, New-York, 2001, pp 2991-3062.
2. BERENSON MM, WELCH V, GARCIA-MARIN JJ: Importance of bile acid structure in amelioration of griseofulvin-induced murine protoporphyric hepatopathy. J Lab Clin Med 118: 89-98, 1991.
3. BLOOMER JR, BONKOVSKY HL, EBERT PS, MAHONEY MJ. Inheritance in protoporphyrin. Comparison of haem synthetase activity in skin fibroblasts with clinical features. Lancet 31: 226-228, 1976.
4. BLOOMER JR, PIERACH CA: Effect of hematin administration to patients with protoporphyria and liver disease. Hepatology 2: 817-821, 1982.
5. m1Pas) in the house mouse. Genomics 16: 645-648, 1993.
6. BRADY AM, LOCK EA. Inhibition of ferrochelatase and accumulation of porphyrins in mouse hepatocyte cultures exposed to porphyrinogenic chemicals. Arch Toxicol 66: 175-181, 1992.
7. CHOI SW, HAN JH, LIM KT, CHO HM, CHUNG KW, SUN HS, PARK DH, KIM BS, SEO EJ: Effect of ursodeoxycholic acid on experimental hepatic porphyria induced by griseofulvin. J Korean Med Sci 6: 146-156, 1991.
8. DELLON ES, SZCZEPIORKOWSKI ZM, DZIK WH, GRAEME-COOK F, ADES A, BLOOMER JR, COSIMI AB, CHUNG RT: Treatment of recurrent allograft dysfunction with intravenous hematin after liver transplantation for erythropoietic protoporphyria. Transplantation 73: 911-915, 2002.
9. FERREIRA GC. Ferrochelatase. Int J of Biochem Cell Biol 31: 995-1000, 1999.
10. FISCHER S, MULLER I, ZUNDT BZ, JUNGST C, MEYER G, JUNGST D: Ursodeoxycholic acid decreases viscosity and sedimentable fractions of gallbladder bile in patients with cholesterol gallstones. Eur J Gastroenterol Hepatol 16: 305-311, 2004.
11. FONTANELLAS A, MAZURIER F, LANDRY M, TAINE L, MOREL C, LAROU M, DANIEL JY, MONTAGUTELLI X, DE SALAMANCA RE, DE VERNEUIL H: Reversion of hepatobiliary alterations by bone marrow transplantation in a murine model of erythropoietic protoporphyria. Hepatology 32: 73-81, 2000.
12. FONTANELLAS A, MENDEZ M, MAZURIER F, CARIO-ANDRE M, NAVARRO S, GED C, TAINE L, GÉRONIMI F, RICHARD E, MOREAU-GAUDRY F, R. EDS, DE VERNEUIL H: Successful therapeutic effect in a mouse model of erythropoietic protoporphyria by partial genetic correction and fluorescence-based selection of hematopoietic cells. Gene Ther 8: 618-626, 2001.
13. GOUYA L, DEYBACH JC, LAMORIL J, DA SILVA V, BEAUMONT C, GRANDCHAMP B, NORDMANN Y: Modulation of the phenotype in dominant erythropoietic protoporphyria by a low expression of the normal ferrochelatase allele. Am J Hum Genet 58: 292-299, 1996.
14. GOUYA L, SCHNEIDER-YIN X, RUFENACHT U, HERRERO C, LECHA M, MASCARO JM, PUY H, DEYBACH JC, MINDER EI: Mutations in the ferrochelatase gene of four Spanish patients with erythropoietic protoporphyria. J Invest Dermatol 111: 406-409, 1998.
15. GOUYA L, PUY H, LAMORIL J, DA SILVA V, GRANDCHAMP B, NORDMANN Y, DEYBACH JC. Inheritance in erythropoietic protoporphyria: A common wild- type ferrochelatase allelic variant with low expression accounts for clinical manifestation. Blood 93: 2105-2110, 1999.
16. GOUYA L, PUY H, ROBREAU AM, BOURGEOIS M, LAMORIL J, DA SILVA V, GRANDCHAMP B, DEYBACH JC: The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat Genet 30: 27-28, 2002.
17. GROSS U, FRANK M, DOSS MO: Hepatic complications of erythropoietic protoporphyria. Photodermatol Photoimmunol Photomed 14: 52-57, 1998.
18. GSCHNAIT F, KONRAD K, HONIGSMANN H, DENK H, WOLFF K: Mouse model for protoporphyria. I. The liver and hepatic protoporphyrin crystals. J Invest Dermatol 65: 290-299, 1975.
19. HENRIKSSON M, TIMONEN K, MUSTAJOKI P, PIHLAJA H, TENHUNEN R, PELTONEN L, KAUPPINEN R: Four novel mutations in the ferrochelatase gene among erythropoietic protoporphyria patients. J Invest Dermatol 106: 346-350, 1996.
20. IRIFUNE H, TSUKAZAKI N, WATANABE M, NONAKA S: The influence of ursodesoxycholic acid (URSO) on griseofulvin (GF)-induced protoporphyria. Nippon Hifuka Gakkai Zasshi 101: 813-817, 1991.
21. KAPPAS A, SASSA S, GALBRAITH RA, NORDMANN Y: The porphyrias. In: The metabolic basis of inherited diseases. CR SCRIVER, AL BEAUDET, WS SLY, D VALLE (eds), Mac Graw-Hill Inc, New-York, 1995, pp 2103-2142.
22. LAMORIL J, BOULECHFAR S, , DE VERNEUIL H, GRANDCHAMP B, NORDMANN Y, DEYBACH JC: Human erythropoietic protoporphyria - 2-point mutations in the ferrochelatase gene. Biochem Biophys Res Commun 181: 594-599, 1991.
23. LIBBRECHT L, MEERMAN L, KUIPERS F, ROSKAMS T, DESMET V, JANSEN P: Liver pathology and hepatocarcinogenesis in a long-term mouse model of erythropoietic protoporphyria. J Pathol 199: 191-200, 2003.
24. LIM HW: Pathophysiology of cutaneous lesions in porphyrias. Semin Hematol 26: 114-119, 1989.
25. MAGNESS ST, BRENNER DA: Targeted disruption of the mouse ferrochelatase gene producing an exon 10 deletion. Biochim Biophys Acta 1453: 161-174, 1999.
26. MAGNESS ST, MAEDA N, BRENNER DA. An exon 10 deletion in the mouse ferrochelatase gene has a dominant-negative effect and causes mild protoporphyria. Blood 100: 1470-1477, 2002.
27. MEERMAN L, KOOPEN NR, BLOKS V, VAN GOOR H, HAVINGA R, WOLTHERS BG, KRAMER W, STENGELIN S, MULLER M, KUIPERS F, JANSEN PLM: Biliary fibrosis associated with altered bile composition in a mouse model of erythropoietic protoporphyria. Gastroenterology 117: 696-705, 1999.
28. NAKAO K, WADA O, TAKAKU F, SASSA S, YANO Y, URATA G: The origin of the increased protoporphyrin in erythrocytes of mice with experimentally induced porphyria. J Lab Clin Med 70: 923-932, 1967.
29. NORDMANN Y, PUY H. Human hereditary hepatic porphyrias. Clin Chim Acta 325: 17-37, 2002.
30. ONAGA Y, IDO A, UTO H, HASUIKE S, KUSUMOTO K, MORIUCHI A, NUMATA M, NAGATA K, HORI T, HAYASHI K, TSUBOUCHI H: Hypermethylation of the wild-type ferrochelatase allele is closely associated with severe liver complication in a family with erythropoietic protoporphyria. Biochem Biophys Res Commun 321: 851-858, 2004.
31. PAUMGARTNER G, BEUERS U: Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis 8: 67-81, 2004.
32. PAWLIUK R, BACHELOT T, WISE RJ, MATHEWS-ROTH MM, LEBOULCH P: Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy. Nat Med 5: 768-773, 1999.
33. PIRLICH M, LOCHS H, SCHMIDT HH: Liver cirrhosis in erythropoietic protoporphyria: improvement of liver function with ursodeoxycholic acid. Am J Gastroenterol 96: 3468-3469, 2001.
34. POH-FITZPATRICK MB, SKLAR JA, GOLDSMAN C, LEFKOWITCH JH: Protoporphyrin hepatopathy. Effects of cholic acid ingestion in murine griseofulvin-induced protoporphyria. J Clin Invest 72: 1449-1458, 1983.
35. POTTER C, TOLAYMAT N, BOBO R, SHARP H, RANK J, BLOOMER J. Hematin therapy in children with protoporphyric liver disease. J Pediatr Gastroenterol Nutr 23: 402-407, 1996.
36. POUPON RE, POUPON R, BALKAU B: Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCAPBC Study Group. N Engl J Med 330: 1342-1347, 1994.
37. RICHARD E, MENDEZ M, MAZURIER F, MOREL C, COSTET P, XIA P, FONTANELLAS A, GERONIMI F, CARIO-ANDRE M, TAINE L, GED C, MALIK P, DE VERNEUIL H, MOREAU-GAUDRY F: Gene therapy of a mouse model of protoporphyria with a self-inactivating erythroid-specific lentiviral vector without preselection. Mol Ther 4: 331-338, 2001.
38. RICHARD E, ROBERT E, CARIO-ANDRE M, GED C, GERONIMI F, GERSON SL, DE VERNEUIL H, MOREAUGAUDRY F: Hematopoietic stem cell gene therapy of murine protoporphyria by methylguanine-DNAmethyltransferase-mediated in vivo drug selection. Gene Ther 11: 1638-1647, 2004.
39. RUFENACHT UB, GOUYA L, SCHNEIDER-YIN X, PUY H, SCHAFER BW, AQUARON R, NORDMANN Y, MINDER EI, DEYBACH JC: Systematic analysis of molecular defects in the ferrochelatase gene from patients with erythropoietic protoporphyria. Am J Hum Genet 62: 1341-1352, 1998.
40. SARKANY RPE, ALEXANDER GJM, COX TM: Recessive inheritance of erythropoietic protoporphyria with liverfailure. Lancet 344: 958-959, 1994.
41. SNYDER AL, SCHMID R: The Conversion of Hematin to Bile Pigment in the Rat. J Lab Clin Med 65: 817-824, 1965.
42. TENHUNEN R, TOKOLA O, LINDEN IB: Haem arginate: a new stable haem compound. J Pharm Pharmacol 39: 780-786, 1987.
43. TUTOIS S, MONTAGUTELLI X, DA SILVA V, JOUAULT H, ROUYER-FESSARD P, LEROY-VIARD K, GUÉNET JL, NORDMANN Y, BEUZARD Y, DEYBACH JC: Erythropoietic protoporphyria in the house mouse - a recessive inherited ferrochelatase deficiency with anemia, photosensitivity, and liver-disease. J Clin Invest 88: 1730-1736, 1991.
44. VAN HATTUM J, BAART DE LA FAILLE H, VAN DEN BERG JW, EDIXHOVEN-BOSDIJK A, WILSON JH. Chenodeoxycholic acid therapy in erythrohepatic protoporphyria. J Hepatol 3: 407-412, 1986.
45. VAN NIEUWKERK CM, ELFERINK RP, GROEN AK, OTTENHOFF R, TYTGAT GN, DINGEMANS KP, VAN DEN BERGH WEERMAN MA, OFFERHAUS GJ: Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. Gastroenterology 111: 165-171, 1996.